Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]
News [3579]
Articles [92]
Editorials [5]
Conferences [157]
elearning [19]
Nivolumab for oesophageal cancer following chemoradiation therapy
Dr Ronan Kelly - Charles A. Sammons Cancer Center, Dallas, USA
Nivolumab for oesophageal cancer following chemoradiation therapy ( Dr Ronan Kelly - Charles A. Sammons Cancer Center, Dallas, USA )
25 Sep 2020
PROFound trial and other recent updates in prostate cancer
Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain
PROFound trial and other recent updates in prostate cancer ( Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
25 Sep 2020
Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma
Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain
Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma ( Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain )
25 Sep 2020
Managing multiple myeloma in a COVID-19 world
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
Managing multiple myeloma in a COVID-19 world ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )
25 Sep 2020
ESMO 2020 renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ESMO 2020 renal roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
25 Sep 2020
ESMO 2020: Lung cancer latest
Prof Solange Peters, Dr Federico Cappuzzo, Dr Antonio Passaro and Prof Sanjay...
ESMO 2020: Lung cancer latest ( Prof Solange Peters, Dr Federico Cappuzzo, Dr Antonio Passaro and Prof Sanjay Popat )
25 Sep 2020
Highlights from ESMO 2020
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Highlights from ESMO 2020 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
25 Sep 2020
Latest in bladder cancer with FGFR 2 and 3 mutations
Dr Yohann Loriot and Dr Scott Tagawa
Latest in bladder cancer with FGFR 2 and 3 mutations ( Dr Yohann Loriot and Dr Scott Tagawa )
24 Sep 2020
PARP inhibitors and their evolving role for the treatment of prostate cancer
Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi
PARP inhibitors and their evolving role for the treatment of prostate cancer ( Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi )
24 Sep 2020
KEYNOTE-590: Pembrolizumab plus chemotherapy for advanced oesophageal cancer
Prof Ken Kato - National Cancer Center Hospital, Chuo-ku, Japan
KEYNOTE-590: Pembrolizumab plus chemotherapy for advanced oesophageal cancer ( Prof Ken Kato - National Cancer Center Hospital, Chuo-ku, Japan )
24 Sep 2020
ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients...
Dr Aditya Bardia - Massachusetts General Hospital, Boston, USA
ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients with previously treated mTNBC ( Dr Aditya Bardia - Massachusetts General Hospital, Boston, USA )
23 Sep 2020
ALTA-1L: Brigatinib vs crizotinib for ALK advanced non small cell lung cancer...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
ALTA-1L: Brigatinib vs crizotinib for ALK advanced non small cell lung cancer patients ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
23 Sep 2020

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation